A scientific review published in the Journal of Pharmaceutical Investigation evaluates molecular engineering, stability hurdles, and formulation designs required to develop long-acting injectable depots for peptide therapeutics. Peptide medicines exhibit high target selectivity and potent biological activity across metabolic, endocrine, oncologic, and rare diseases, but their therapeutic delivery remains constrained by rapid renal clearance, short systemic half-lives, proteolytic degradation, and limited residence within target tissues.
Long-acting injectable depots offer a pathway to reduce dosing frequency and improve treatment persistence among patients, yet formulation development faces substantial obstacles. The researchers report that peptide hydrophilicity, structural fragility, and high formulation sensitivity complicate depot engineering. Overcoming these barriers requires coordinating chemical and structural modifications with specialized vehicle matrices rather than relying on standard sustained-release delivery vehicles.
The review details multiple molecular engineering strategies designed to improve metabolic stability, in vivo persistence, self-assembly behaviors, and formulation compatibility. These approaches encompass modifications to peptide sequences, terminal sequence extensions, backbone alterations, conformational constraints, prodrug formats, and polymer or lipid conjugations. Each structural intervention aims to counteract specific enzymatic, chemical, physical, and depot-associated degradation pathways that otherwise compromise therapeutic molecules.
Addressing chemical, physical, and depot-induced instability requires establishing clear relationships among peptide physicochemical properties, formulation architecture, sustained release kinetics, and long-term storage stability. The authors examine manufacturing processes, sterility considerations, and specialized in vitro release testing protocols that employ biorelevant release conditions to monitor drug dissolution and structural integrity over extended durations.
Establishing dependable translational links between laboratory testing and living systems represents a critical developmental requirement. The review highlights the relevance of in vitro–in vivo correlation and in vitro–in vivo relationship frameworks to link observed in vitro release behavior with actual in vivo pharmacokinetic performance. Robust predictive models are necessary to ensure that release profiles measured in controlled laboratory environments accurately reflect systemic drug exposure.
In their expert opinion, the authors conclude that long-acting injectable peptides must be developed as integrated drug delivery systems rather than simple sustained-release preparations. Because intrinsic molecular properties directly dictate depot formation, drug release kinetics, and long-term product stability, molecular engineering and formulation design must be aligned at early development stages. Tailoring long-acting strategies to each peptide’s specific degradation liabilities, physicochemical properties, target dosing interval, and release profile—incorporating tools such as D-amino acid substitution, lactam-bridge macrocyclization, lipidation, polyethylene glycol conjugation, Quality by Design process control, and model-informed development—provides a systematic framework for reliable product engineering.
To counteract specific enzymatic and chemical degradation routes, the evaluation emphasizes that molecular modifications must be carefully coordinated with formulation needs. Applying conformational strategies, backbone alterations, or sequence adjustments such as D-amino acid substitutions directly addresses the vulnerability of peptide drugs to rapid proteolytic degradation. Similarly, incorporating terminal sequence extensions, prodrug designs, or lactam-bridge macrocyclization alters structural properties to enhance metabolic stability and sustain tissue residence. Conjugation methods, including lipidation and polyethylene glycol attachment, further alter molecular characteristics to extend in vivo persistence and control self-assembly, ensuring the peptide remains compatible with the chosen depot environment.
The physical fragility and inherent hydrophilicity of peptide therapeutics introduce complex hurdles during depot preparation and storage. Chemical, physical, and depot-associated degradation pathways can compromise the active molecule unless manufacturing workflows and sterility considerations are tailored to the physical characteristics of each agent. Achieving sustained release over extended intervals requires balancing these intrinsic peptide properties against the vehicle matrix to preserve long-term stability. When formulation architecture fails to accommodate molecular sensitivity, depot formation can be impaired, disrupting the intended release rate and undermining overall therapeutic persistence across long dosing intervals.
To ensure laboratory observations translate into predictable clinical exposure, testing protocols rely on biorelevant release conditions to assess depot behavior over time. Establishing in vitro–in vivo correlation (IVIVC) and in vitro–in vivo relationship (IVIVR) models enables researchers to link laboratory dissolution profiles directly to in vivo pharmacokinetic performance. Implementing Quality by Design (QbD)-based process controls alongside model-informed development provides a systematic basis for managing degradation liabilities, verifying sterility, and adjusting delivery mechanics to achieve the target dosing interval required for effective metabolic, endocrine, oncologic, or rare disease interventions.
Subject of Research: Molecular engineering and formulation strategies for long-acting injectable peptide depots
Article Title: Designing peptide therapeutics for long-acting injectable depots: molecular engineering, stability challenges, and formulation strategies
Article References: Lee, J. H., Go, Y. M., Lee, J.-H., & Ahn, J.-H. (2026). Designing peptide therapeutics for long-acting injectable depots: molecular engineering, stability challenges, and formulation strategies. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00839-w
Image Credits: AI Generated
DOI: 10.1007/s40005-026-00839-w
Keywords: peptide therapeutics, long-acting injectables, depot formulations, molecular engineering, proteolytic degradation, renal clearance, lactam-bridge macrocyclization, lipidation, polyethylene glycol conjugation, D-amino acid substitution, terminal sequence extension, in vitro release testing, in vitro-in vivo correlation, in vitro-in vivo relationship, Quality by Design, model-informed development, biorelevant release conditions, pharmacokinetic performance
News Source: Ophelia Keating. (November 15, 2026). Review Recommends Early Molecular and Formulation Integration for Long-Acting Peptide Depots. Scienmag.



